Literature DB >> 3655915

Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man.

J C Sisson1, B Shapiro, L Meyers, S Mallette, T J Mangner, D M Wieland, J V Glowniak, P Sherman, W H Beierwaltes.   

Abstract

Metaiodobenzylguanidine (MIBG) localizes in adrenergic neurons; MIBG labeled with 123I then serves as an analog of norepinephrine, and concentrations of [123I]MIBG reflect sites of adrenergic neurons in organs. Movements of [123I]MIBG into and out of organs were measured by quantitative scintigraphy in man. We perturbed adrenergic neuron function in several ways, and [123I]MIBG concentrations in the heart were subsequently altered in patterns consistent with the concept that [123I]MIBG resides mostly in adrenergic neurons. Uptake of [123I]MIBG into the heart was inhibited by the tricyclic drug, imipramine, and this agent also accelerated the rate of loss of [123I]MIBG. Phenylpropanolamine, a sympathomimetic drug that acts by displacing norepinephrine from neurons, increased the rates of loss of [123I]MIBG from the heart. Exercise was followed by a movement of [123I]MIBG into blood and urine. Generalized autonomic neuropathies were associated with marked diminutions of [123I]MIBG uptake into the heart. We conclude that quantitative scintigraphy in patients will enable determinations of regional disturbances in integrity (by measuring uptake of [123I]MIBG) and function (by measuring rates of loss of [123I]MIBG) of the adrenergic nervous system in the heart.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3655915

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  69 in total

Review 1.  MIBG imaging.

Authors:  Amar D Patel; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

2.  Carvedilol improves left ventricular function in heart failure patients with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidine.

Authors:  Myron C Gerson; Laura L Craft; Nancy McGuire; Damodhar P Suresh; William T Abraham; Lynne E Wagoner
Journal:  J Nucl Cardiol       Date:  2002 Nov-Dec       Impact factor: 5.952

3.  Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors.

Authors:  Lucia Martiniova; Shiromi M Perera; Frederieke M Brouwers; Salvatore Alesci; Mones Abu-Asab; Amanda F Marvelle; Dale O Kiesewetter; David Thomasson; John C Morris; Richard Kvetnansky; Arthur S Tischler; James C Reynolds; Antonio Tito Fojo; Karel Pacak
Journal:  Endocr Relat Cancer       Date:  2011-01-13       Impact factor: 5.678

4.  Interaction of metaiodobenzylguanidine with cardioactive drugs: an in vitro study.

Authors:  F Huguet; D Fagret; M Caillet; A Piriou; J C Besnard; D Guilloteau
Journal:  Eur J Nucl Med       Date:  1996-05

Review 5.  Non-invasive evaluation of arrhythmic risk in dilated cardiomyopathy: From imaging to electrocardiographic measures.

Authors:  Massimo Iacoviello; Francesco Monitillo
Journal:  World J Cardiol       Date:  2014-07-26

6.  Impairments of myocardial sympathetic activity may reflect the progression of myocardial damage or dysfunction in hypertrophic cardiomyopathy.

Authors:  Shinro Matsuo; Yasuyuki Nakamura; Takayoshi Tsutamoto; Masahiko Kinoshita
Journal:  J Nucl Cardiol       Date:  2002 Jul-Aug       Impact factor: 5.952

7.  A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies.

Authors:  M Yoshita; J Taki; M Yamada
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-11       Impact factor: 10.154

Review 8.  Cardiac metaiodobenzylguanidine imaging and heart failure.

Authors:  Tomoaki Nakata; Akiyoshi Hashimoto; Hirohito Sugawara
Journal:  Curr Heart Fail Rep       Date:  2013-12

9.  Long-term course and cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy.

Authors:  M Shimizu; N Sugihara; Y Kita; K Shimizu; Y Horita; K Nakajima; J Taki; R Takeda
Journal:  Br Heart J       Date:  1992-02

10.  Activity of the uptake-1 norepinephrine transporter as measured by I-123 MIBG in heart failure patients with a loss-of-function polymorphism of the presynaptic alpha2C-adrenergic receptor.

Authors:  Myron C Gerson; Lynne E Wagoner; Nancy McGuire; Stephen B Liggett
Journal:  J Nucl Cardiol       Date:  2003 Nov-Dec       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.